Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
41556616 (PubMed )
Supplement: PRO-35-e70422-s002.xlsx › Table_S1
EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates.
Sentana-Lledo D et al.
Translational Lung Cancer Research, 2023
A review of HER2 overexpression and somatic mutations in cancers.
Galogre M et al.
Critical Reviews in Oncology/hematology, 2023
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
37168365 (PubMed )
Supplement: Table_4.xlsx › ERBB2_mutations
Targeting HER2 genomic alterations in non-small cell lung cancer.
Zeng J et al.
Journal of the National Cancer Center, 2021
Spatially interacting phosphorylation sites and mutations in cancer.
Huang KL et al.
Nature Communications, 2021
33875650 (PubMed )
Supplement: 41467_2021_22481_MOESM4_ESM.xlsx › TableS5.ActMutationClusters
Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.
Wei XW et al.
Thoracic Cancer, 2020
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.
Liao RG et al.
Cancer Research, 2013
Select a paper to view details